661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile

BACKGROUND: Omadacycline was approved for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in 2018. Previous studies demonstrate that omadacycline has in vitro activity against Clostridioides difficile. We determined the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Skinner, Andrew M, Petrella, Laurica A, Cheknis, Adam K, Johnson, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752168/
http://dx.doi.org/10.1093/ofid/ofac492.713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752168/
http://dx.doi.org/10.1093/ofid/ofac492.713

Ejemplares similares